GLP-1 Clinical Relevance #34Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical TrialComparative Effectiveness StudyWeight LossTirzepatideMazdutideEndocrinologyAdults with ObesityWeight Management OutcomesGLP-1 Receptor AgonistDual GIP-GLP-1 Receptor AgonistGlucose MetabolismCardiovascular...
Endocannabinoid System Research: CBD Glucose Study
Clinical Takeaway CBD supplementation at low doses for a short duration did not improve glucose tolerance or alter gut microbiota composition in overweight or obese adults, despite theoretical mechanisms suggesting potential benefit....
Endocannabinoid System Research: CBD and Glucose
Clinical Takeaway Clinical Takeaway In sedentary adults with overweight or obesity, short-term low-dose CBD treatment did not produce measurable improvements in glucose tolerance or alterations to gut microbiome composition. These pilot findings...
Cannabinoid Clinical Trials: CBD, Glucose & Gut Health
Clinical Takeaway In this pilot study, short-term low-dose CBD supplementation did not produce measurable improvements in glucose tolerance, gut microbiome composition, or inflammatory markers in sedentary adults with overweight or obesity. While...
Tetrahydrocannabinol-Rich Extracts From Cannabis Sativa L. Improve Glucose Consumption and Modulate Metabolic Complications Linked to Neurodegenerativ
Tetrahydrocannabinol (THC), a major constituent of the plant cannabis, can interact with endocannabinoid receptors abundant on neurons, thereby affecting multiple neuronal processes. In particular, a group of scientists recently investigated the ability...